Rami Katra

Dr. Rami Katra

orcid

Research Focus & Metrics

Academic Career Length

13Years (2014-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
7 December 2020 in Thyroid®
Verified
Journal Article
Closed access
BPBarbora Pekova
Barbora Pekova
VSVlasta Sykorova
Vlasta Sykorova
SDSarka Dvorakova
Sarka Dvorakova
EVEliska Vaclavikova
Eliska Vaclavikova
JMJitka Moravcova
Jitka Moravcova
BBBela Bendlova
Bela Bendlova
Background: Pediatric papillary thyroid carcinoma (PTC) is a rare malignancy, but with increasing incidence. Pediatric PTCs have distinct clinical and pathological features and even the molecular profile differs from adult PTCs. Somatic point mutations in pediatric PTCs have been previously described and studied, but complex information about fusion genes is lacking. The aim of this study was to identify different fusion genes in a large cohort of pediatric PTCs and to correlate them with clinical and pathological data of patients. Methods: The cohort consisted of 93 pediatric PTC patients (6–20 years old). DNA and RNA were extracted from fresh frozen tissue samples, followed by DNA and RNA-targeted next-generation sequencing analyses. Fusion gene-positive samples were verified by real-time polymerase chain reaction. Results: A genetic alteration was found in 72/93 (77.4%) pediatric PTC cases. In 52/93 (55.9%) pediatric PTC patients, a fusion gene was detected. Twenty different types of RET , NTRK3 , ALK , NTRK1 , BRAF , and MET fusions were found, of which five novel, TPR/RET , IKBKG/RET , BBIP1/RET , OPTN/BRAF , and EML4/MET , rearrangements were identified and a CUL1/BRAF rearrangement that has not been previously described in thyroid cancer. Fusion gene-positive PTCs were significantly associated with the mixture of classical and follicular variants of PTC, extrathyroidal extension, higher T classification, lymph node and distant metastases, chronic lymphocytic thyroiditis, and frequent occurrence of psammoma bodies compared with fusion gene-negative PTCs. Fusion-positive patients also received more doses of radioiodine therapy. The most common fusion genes were the RET fusions, followed by NTRK3 fusions. RET fusions were associated with more frequent lymph node and distant metastases and psammoma bodies, and NTRK3 fusions were associated with the follicular variant of PTC. Conclusions: Fusion genes were the most common genetic alterations in pediatric PTCs. Fusion gene-positive PTCs were associated with more aggressive disease than fusion gene-negative PTCs.

16 April 2021 in Cancers
Verified
Journal Article
Open access
PDF file
BPBarbora Pekova
Barbora Pekova
VSVlasta Sykorova
Vlasta Sykorova
KMKarolina Mastnikova
Karolina Mastnikova
EVEliska Vaclavikova
Eliska Vaclavikova
JMJitka Moravcova
Jitka Moravcova
BBBela Bendlova
Bela Bendlova
Chromosomal rearrangements of NTRK genes are oncogenic driver mutations in thyroid cancer (TC). This study aimed to identify NTRK fusion-positive thyroid tumors and to correlate them with clinical and pathological data and determine their prognostic significance. The cohort consisted of 989 different TC samples. Based on the detected mutation, samples were triaged, and those that were positive for a BRAF, HRAS, KRAS, NRAS, RET, RET/PTC or PAX8/PPARγ mutation were excluded from further analyses. NTRK fusion gene testing was performed in 259 cases, including 126 cases using next-generation sequencing. NTRK fusion genes were detected in 57 of 846 (6.7%) papillary thyroid carcinomas and in 2 of 10 (20.0%) poorly differentiated thyroid carcinomas. A total of eight types of NTRK fusions were found, including ETV6/NTRK3, EML4/NTRK3, RBPMS/NTRK3, SQSTM1/NTRK3, TPM3/NTRK1, IRF2BP2/NTRK1, SQSTM1/NTRK1 and TPR/NTRK1.NTRK fusion-positive carcinomas were associated with the follicular growth pattern, chronic lymphocytic thyroiditis and lymph node metastases. NTRK1-rearranged carcinomas showed a higher frequency of multifocality and aggressivity than NTRK3-rearranged carcinomas. Tumor size, presence of metastases, positivity for the NTRK3 or NTRK1 fusion gene and a late mutation event (TERT or TP53 mutation) were determined as factors affecting patient prognosis. NTRK fusion genes are valuable diagnostic and prognostic markers.

1 August 2014 in International Journal of Pediatric Otorhinolaryngology
Verified
Journal Article
Closed access
RKRami Katra
Rami Katra
ZKZ. Kabelka
Z. Kabelka
MJM. Jurovcik
M. Jurovcik
OHO. Hradsky
O. Hradsky
JKJ. Kraus
J. Kraus
JAJ. Astl
J. Astl

16 September 2024 in Thyroid®
Verified
Journal Article
Open access
KMKarolina Mastnikova
Karolina Mastnikova
BPBarbora Pekova
Barbora Pekova
VKVlasta Kuklikova
Vlasta Kuklikova
EVEliska Vaclavikova
Eliska Vaclavikova
JCJitka Carkova
Jitka Carkova
BBBela Bendlova
Bela Bendlova
Background: Recent studies have suggested that pathogenic variants of the DICER1 gene could be a driver of alterations in some pediatric thyroid nodules, but data are still limited. The aim of this study was to detect variants in the DICER1 gene in a large cohort of pediatric thyroid nodules and then correlate them with clinicopathological data, with a focus on the disease prognosis in patients with thyroid carcinoma. Methods: This retrospective cohort study consisted of 350 pediatric and young adult patients (aged 2–21 years) with thyroid nodules, from whom 275 fresh-frozen thyroid nodule samples and 92 fine-needle aspiration biopsy (FNAB) samples were collected. After an analysis of variants in major genetic alterations of thyroid tumors, variants in the DICER1 gene were identified using next-generation sequencing and multiplex ligation-dependent probe amplification methods. Peripheral blood was analyzed from patients with DICER1 -positive tumors. The results of genetic analysis were then correlated with clinicopathological data. Results: Variants in the DICER1 gene were detected in a total of 24/350 (6.9%; 95%CI [4.4;10.0]) pediatric and young adult patients, respectively, in 10/119 (8.4%; [4.1;14.9]) patients with benign fresh-frozen tissue, in 8/141 (5.7%; [1.9;9.5]) with papillary thyroid carcinoma (PTC) and in 6/86 (7.0%; [4.1;14.6]) patients with FNAB. No other gene alteration was found in DICER1 -positive samples. Germline DICER1 variants were identified in 11/24 (45.8%; [25.6;67.2]) patients. Two somatic (biallelic) variants in the DICER1 gene were found in 9/24 (37.5%; [18.8;59.4]) thyroid nodules. Somatic deletions of at least 3 Mbp long were revealed in 2/24 (8.3%; [1.0;27.0]) cases. DICER1 -positive PTCs were significantly associated with the follicular subtype of PTC ( p = 0.001), encapsulation ( p = 0.006) and were larger in size ( p = 0.035), but with no extrathyroidal extension ( p = 0.039), and less frequent lymph node metastases ( p = 0.003) compared with DICER1 -negative PTCs. Patients with DICER1- positive PTC had an excellent response to treatment in 75% of cases. Conclusions: Variants of the DICER1 gene are frequently found in the thyroid nodules of pediatric and young adult patients. In our patients, DICER1 -positive PTCs showed low invasiveness. Our findings support considering more conservative management for DICER1 -positive low-risk PTCs.

2 September 2022 in Endocrine Abstracts
Verified
Journal Article
Closed access
KMKarolina Mastnikova
Karolina Mastnikova
BPBarbora Pekova
Barbora Pekova
VSVlasta Sykorova
Vlasta Sykorova
JMJitka Moravcova
Jitka Moravcova
EVEliska Vaclavikova
Eliska Vaclavikova
BBBela Bendlova
Bela Bendlova
Objectives: Variants in the EIF1AX gene have been reported in malignant as well as benign thyroid nodules and their clinical significance is still unclear due to their low prevalence. The aim of this study was to identify EIF1AX variants in a large cohort of different types of thyroid nodules and to correlate them with clinical and pathological data. Methods: The study consisted of 904 thyroid nodule samples. The cohort included 577 papillary thyroid carcinomas (PTCs), 16 anaplastic thyroid carcinomas (ATCs), 8 poorly differentiated thyroid carcinomas (PDTCs), 18 follicular thyroid carcinomas (FTCs), 10 oncocytic carcinomas, 35 borderline lesions (e.g., follicular tumor of uncertain malignant potential - FT-UMP), 55 follicular thyroid adenomas (FTA) and 185 benign nodules. DNA isolated from fresh frozen thyroid tissues was used for preparation of libraries using the Nextera XT DNA Library Prep Kit (Illumina, USA) and analyzed using next-generation sequencing (MiSeq, Illumina, USA). Variants in the EIF1AX gene (exons 1, 2, 5, 6) were visualized in Integrative Genomics Viewer (Broad Institute, USA) and evaluated by VarSome platform (Saphetor SA, Switzerland). Results: EIF1AX gene variants were detected in 18 of 904 thyroid samples (2%) - 2 ATCs, 3 PTCs, 2 FTCs, 2 FTAs, 2 FT-UMPs, 1 oncocytic adenoma and 6 other benign nodules. The most frequent EIF1AX A113_splice variant was found in 6 of 18 (33.3%) positive samples (1 ATC, 2 PTC, 1 FTA, 1 FT-UMP and 1 goiter). Variants in codon 9 (G9R, G9V, G9D) of EIF1AX gene were found in 3 benign nodules and 1 ATC, in which coexisted with variants of TERT, TP53 and NRAS genes. The coexistence of EIF1AX variants with mutations in other genes (5× TERT, 9× RAS – 4 × simultaneously) was found in a total of 10 of 18 cases, and often correlated with more aggressive disease. On the other side, 8 EIF1AX-positive samples which did not possess other driver mutations were benign nodules, FTAs or FT-UMPs. Conclusion: In summary, EIF1AX gene variants were detected in 18 cases. In most cases, the EIF1AX variants co-occurred with known variants of other genes and were associated with more aggressive tumor behavior. In accordance with literature, distinct EIF1AX variants may be related to different types of thyroid tumors and extension of the positive cohort could provide more accurate insight into the understanding of this gene. Supported by AZV NU21-01-00448 and MH CR RVO 00023761.

2 September 2022 in Endocrine Abstracts
Verified
Journal Article
Closed access
BPBarbora Pekova
Barbora Pekova
VSVlasta Sykorova
Vlasta Sykorova
KMKarolina Mastnikova
Karolina Mastnikova
EVEliska Vaclavikova
Eliska Vaclavikova
JMJitka Moravcova
Jitka Moravcova
BBBela Bendlova
Bela Bendlova
Objectives: RET fusion genes are known driver mutations in papillary thyroid carcinomas (PTCs) and have been described mainly in pediatric PTCs, in which they represent the most common genetic alteration. The aims of this study were to identify RET fusion genes in PTCs (from pediatric as well as adult patients), to correlate them with clinical and histopathological features and to determine the prognostic significance of RET fusion genes based on long-term follow-up of patients with PTC harboring this mutation. Methods: The cohort consisted of 920 PTC samples (fresh frozen tissues) from pediatric and adult patients. Based on the detected mutation, samples were triaged. Samples positive for the BRAF, HRAS, KRAS, NRAS or NTRK fusion gene mutations were excluded from the further RET fusion gene analyses. Samples were analyzed for the presence of RET fusion genes using Real-Time PCR (LC480, Roche) or using the FusionPlex Comprehensive Thyroid and Lung panel (ArcherDx) by next generation sequencing (MiSeq, Illumina). Results: RET fusion genes were detected in 108 (11.7%) PTCs, from which 34/121 (28.1%) were from pediatric and adolescent patients (7-20 years old) and 74/799 (9.3%) were from adult patients. The mean age of diagnosis was 33.0 ± 17.1 years. A total of 20 types of RET fusions were found, including the following partner genes: CCDC6, NCOA4, PRKAR1A, SQSTM1, IKBKG, RASAL2, TPR, ACBD5, RUFY2, BBIP1, AFAP1L2, AKAP13, TRIM27, SPECC1L, FBXO41, GOLGA5, SSBP2, ZMYM2, ERC1, KIAA1217. The RET fusion-positive carcinomas were associated with infiltrative tumor growth, numerous intrathyroidal micrometastases, psammoma bodies, lymph node and distant metastases. Lymph node metastases were found in 31/34 (91.2%) pediatric cases and in 52/71 (73.2%) adult patients. Distant metastases were identified in 9/34 (26.5%) pediatric patients and 11/69 (15.9%) adult patients. Patients responded well to radioiodine treatment, radioiodine-refractory PTCs harboring RET fusions were rare. Three patients (2.8%) died of the disease, in two cases was carcinoma positive for NCOA4/RET and in one case for CCDC6/RET with a TERT C250T co-alteration. Conclusion: In summary, RET fusion genes are an important genetic marker in PTCs associated with aggressive tumor behavior and frequent metastases. RET fusions occurred approximately three times more frequently in pediatric and adolescent patients, in which carcinomas were more advanced, than in adult patients. In conclusion, the genetic molecular testing of RET fusions is important for patient’s diagnosis and prognosis and also for possible targeted therapy. Supported by AZV NU21-01-00448 and MH CR RVO 00023761.